WELL Health
TECHNOLOGIES CORP

Q3-2026 Earnings Presentation

November 9, 2026



Disclaimer

Forward-Looking Information
This presentation contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws (collectively, "forward-looking information") concerning WELL Health Technologies Corp. and its subsidiaries ("WELL Health" or the "Company"). Forward-looking information is based on management's current expectations and assumptions regarding demand for healthcare, customer adoption and retention, government funding and procurement, regulatory approvals, timely and cost-effective product development and deployment, access to third-party technology and data, continued support from its subsidiaries and third parties, acquisition and financing opportunities, successful integration, personnel and operating costs, and stable legal, reimbursement and market conditions.

Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with: primary healthcare sector in general; competition; that future results may vary from historical results; the availability and effective integration and operation of management information systems and other technologies; ability to mitigate against cyber security risks; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws; and government regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this presentation. Readers are cautioned that the foregoing list of factors is not exhaustive.

Management considers its expectations and assumptions reasonable as of this presentation's date, but actual outcomes are not assured. Planned products and capabilities may change or never become commercially available. Forward-looking information reflects management's current expectations and plans, may not be appropriate for other purposes and should not be unduly relied upon. Except as required by applicable securities laws or the Toronto Stock Exchange policies, the Company undertakes no obligation to update it.

Non-IFRS Financial Measures and Other Financial Metrics
This presentation includes Adjusted EBITDA, Adjusted Shareholder EBITDA, Normalized Adjusted EBITDA, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income, Adjusted Free Cash Flow (Adjusted FCF), Adjusted Free Cash Flow Attributable to Shareholder (Adjusted FCFA2S), and other metrics including organic revenue growth. Management uses these measures to assess performance, revenue characteristics and growth. Non-IFRS measures and ratios have no standardized meanings under IFRS Accounting Standards, may not be comparable to those of other issuers and should not replace or be considered in isolation from IFRS measures. Other metrics may also be calculated differently by other issuers. Historical performance does not guarantee future results.

Market Data and Operating Estimates
Market and industry information derives from both internal and third-party sources management believes to be reasonable; third-party information has not been independently verified. Market-size estimates depend on assumptions and do not forecast Company revenue. Operating statistics and estimated time savings, patient visits, efficiencies and revenue recovery depend on the population, methodology and period assessed. Actual customer outcomes vary with configuration, adoption, practice characteristics and other circumstances.

Today’s Speakers

Hamed Shahbazi

Chief Executive Officer



Evelyn Sutherland

Chief Financial Officer



Q3 Highlights

A quarter of underlying earnings growth and strategic milestones

+20%

Normalized Adjusted EBITDA[1] growth

2026 GUIDANCE[2]

~$1.58B Revenue

$185–195M Adjusted EBITDA

HIGHLIGHTS:

1. **WELL Canadian Clinics Achieve Milestone of $100 Million Annualized Adjusted EBITDA Run-Rate**
2. **Completed WELLSTAR TSXV Listing, Eliminating $155M of Preferred Shares[3] Liabilities from WELL's Balance Sheet**
3. **Completed $150M Bond Offering**
4. **Competition Bureau No Action Letter**

(1) Normalized figures include no Circle Medical revenue deferral impacts in Q3-2026 and the normalization for $17.6 million of impacts in Q3-2025.
(2) This guidance includes the effect of $17.6 million in deferred revenue from Circle Medical to be recognized in 2026. For more information regarding this impact, please refer to WELL's Q3-26 MD&A.
(3) Carrying value of WELLSTAR Series A and Series B redeemable preferred shares converted into WELLSTAR Subordinated Voting Shares.

WELL Q3-2026 Key Financial Highlights[1]

Q3 Revenue

$407.4M

NORMALIZED Y/Y

+17%

Reported +12% Y/Y

Q3 Adj. EBITDA

$50.9M

NORMALIZED Y/Y

+20%

Reported −15% Y/Y

Q3 Adj. Sh. EBITDA

$34.8M

NORMALIZED Y/Y

+13%

Reported −19% Y/Y

Q3 Adj. Gross Profit

$177.8M

NORMALIZED Y/Y

+20%

Reported +7% Y/Y

Q3 Adj. Gross Margin

43.7%

NORMALIZED Y/Y

+100 bps

Reported −180 bps Y/Y

Q3 Adj. Net Income

$27.3M

NORMALIZED Y/Y

−15%

Reported −33% Y/Y

(1) Normalized figures include no Circle Medical revenue deferral impacts in Q3-2026 and the normalization for $17.6 million of impacts in Q3-2025.

WELL Health TECHNOLOGIES CORP

WELL Q3-2026 Operational Highlights[1]

$100M+

CANADIAN CLINICS

Annualized Adjusted EBITDA run-rate achieved one quarter ahead of plan

CANADIAN CLINIC PLATFORM

3,400+

Providers in WELL's Canadian Clinic Network

1,500+ physicians in Canada

1.3M

Patient visits in Canada

+20% YoY | +6% organic

179

Physical facilities[2] in Canada

US OPERATIONS

1,500+

Providers in WELL's US Clinic Network

500+ physicians in the US

665K

Patient visits in the US

+1% QoQ | +4% organic

152

ASCs / GI clinics served by CRH

(1) All figures exclude HEALWELL AI and WELLSTAR.

(2) A physical facility is a distinct physical location from which WELL delivers care. A single physical facility may house multiple clinics. Excludes WELL Affiliate Clinics.

Making a Positive Impact on Canadian Healthcare

Technology-enabled care is advancing patient engagement, clinical efficiency and patient experience across Canada.



84

NPS at WELL Clinics

in Q3-2026 vs. 34 industry average[1]



520K+

eReferrals Processed

in Q3-2026 at WELLSTAR



62K+

Patient Records Screened

for disease detection in Q3-2026 by HEALWELL at WELL Clinics



120K+


WELLTRUST Consents

collected as of October 31, 2026

(1) See Retently, "What is a Good Net Promoter Score? (2026 NPS Benchmark)" published on April 15, 2026.

WELL Health TECHNOLOGIES CORP

OneWELL: One Integrated Platform to Address Canada's Healthcare Needs



ONE INTEGRATED STACK

One partner across the health system – not a patchwork of point solutions.


- **Primary Care Clinics**
- **EMR**
- **Health Information Exchange**
- **Diagnostic Centres**
- **eReferral / eConsult**
- **AI Decision Support**

Canada's Partner for Key Public Sector Priorities

Provinces are prioritizing access, attachment, wait times and efficiency – OneWELL is built for this moment

>$100M

Engaged Contract Value[1]



What Public Health is Solving for

- **Access:** Timely care when and where patients need it
- **Attachment:** Connecting unattached patients to primary care
- **Wait Times:** Faster specialist referral and consult
- **Efficiency:** Lower system cost through digital tools

Why OneWELL Wins

- **Care + Technology:** We deliver care and build the tools
- **Canadian and Sovereign:** Patient data stays in Canada
- **Interoperable and Modular:** Scales from clinic to province

(1) Management's estimate of potential revenue from public sector opportunities under active pursuit. These opportunities have not been awarded and may not result in contracts or revenue. Forward-looking information; see "Disclaimer".

Strengthened Balance Sheet with $150M Bond Offering

Extends debt maturity to 2031 and optimizes capital structure to support continued growth in Canada.

$150M	6.875%	2031	July 15, 2026
Senior Unsecured	Coupon (per annum)	Maturity (5-year Notes)	Closed

- Early redemption of $70M convertible debentures (August 19, 2026)
- WELL's inaugural senior unsecured notes offering
- Extends debt maturity profile to 2031
- Ranks equally with other senior unsecured debt

WELLSTAR Listing: De-levering WELL and Unlocking Value

Trading commenced October 1, 2026 (TSXV: WSTR), removing WELLSTAR's ~$155M[1] of redeemable preferred shares from WELL's balance sheet.

~$469M
Market Cap[2]

$93.0M
Cash with No Debt or Preferred Shares[3]

+33%
Q3-2026 YoY Revenue Growth

$83.7M
ARR[4] in Q3-2026 (+27% YoY)

De-levering WELL	**~$155M[1] of preferred shares converted into shares**
Unlocking value for WELL	**Public market value for WELLSTAR established, currently ~$469M market cap[2]**
Strong balance sheet	**$93.0M of cash and no debt[3]**


(1) Carrying value of WELLSTAR Series A and Series B redeemable preferred shares converted into WELLSTAR Subordinated Voting Shares.
(2) Fully diluted, based on a closing share price of $5.93 as of November 6, 2026.
(3) As at September 30, 2026.
(4) ARR (Annual Recurring Revenue) is a supplementary financial measure representing the annualized value of recurring subscription, support, maintenance, platform access and recurring billing or revenue cycle management arrangements in effect at period end.

WELL Health TECHNOLOGIES CORP

WELL YTD-2026 Canadian Clinics Financial Performance


WELL Canadian Clinics Annual Revenue Growth

(C$ in 000s)




WELL Canadian Clinics Annual Adj. EBITDA Growth

(C$ in 000s)



WELL Canadian Clinics Count[1,2]



(1) A clinic is a distinct healthcare service, defined by its brand, business or P&L, care team or EMR. A single physical facility may house multiple clinics. As at September 30, 2026, WELL operated 302 clinics across 179 physical facilities, excluding WELL Affiliate Clinics.


(2) Net clinic count decreased QoQ from 304 to 302, reflecting the consolidation of a small number of locations into other WELL clinics to improve utilization while maintaining physician and patient coverage.

WELL Health TECHNOLOGIES CORP

WELL Q3-2026 Canadian Clinics Financial Performance


WELL Canadian Clinics Q3-2026 Revenue[1] Growth

(C$ in OOOs)



WELL Canadian Clinics Q3-2026 Adj. EBITDA Growth

(C$ in OOOs)




(1) Includes intercompany revenue


WELL Providers Are Seeing More Patients

WELL Canadian Clinics Patient Visits[1,2]


Values in OOOs



Billable Providers in WELL's Canadian Clinics Network[2]



Patient Visits / Billable Provider



(1) *A patient visit is defined as a completed patient encounter with a billable provider in WELL's Canadian clinics network, delivered in person or virtually, across primary care, specialty care, allied health and diagnostic services.*
(2) *Excludes eConsult consultations from WELL's eConsult business acquired in February 2026.*

WELL Health TECHNOLOGIES CORP

Canadian Clinic Recent M&A Activity and Pipeline

Integration-focused Q3-2026 following an active first half of Canadian Clinic M&A

YTD-2025	YTD-2026
+19 Clinics 12 transactions	**+27 Clinics** 7 transactions
+$67.0M Annual Revenue	**+$102.0M** Annual Revenue
+198 Providers Total Canadian Clinics	**+203 Providers** Total Canadian Clinics

WELL Canadian Clinics Total Pipeline[1]

$390 Million+ Revenue

20+ Targets Engaged

100+ Clinics

(1) The Total WELL Canadian Clinics Pipeline includes potential deals that are under LOI and in the pre-LOI stage (does not include WELLSTAR or HEALWELL pipelines).

WELL Health TECHNOLOGIES CORP

Strategic Alternatives Processes for US Assets


CRH Medical CORPORATION
A WELL Health Company

wisp

Circle Medical

Q3-2026 Financial Highlights: Revenue


Revenue bridge from Q3-2025 to Q3-2026



(1) Normalized figures include no Circle Medical revenue deferral impacts in Q3-2026 and the normalization for $17.6 million of impacts in Q3-2025.

Q3-2026 Financial Highlights: Adjusted EBITDA

Adjusted EBITDA bridge from Q3-2025 to Q3-2026




(1) Normalized figures include no Circle Medical revenue deferral impacts in Q3-2026 and the normalization for $17.6 million of impacts in Q3-2025.

Q3-2026 Financial Highlights: Adjusted Net Income[1]

Bridge from Net Income to Adjusted Net Income for Q3-2026

(C$ in 000,000s)




(1) Adjusted Net Income is net income (loss) adjusted to remove the impact of non-cash items, non-recurring or non-operational gains and losses, and revenue timing differences that do not reflect the Company's underlying operating performance.

Q3-2026 Financial Highlights: Adjusted FCF[1] and FCFA2S[2]

Bridge from Adjusted EBITDA to FCF and FCFA2S for Q3-2026

(C$ in 000,000s)



(1) *The Company defines Adjusted Free Cash Flow as Adjusted EBITDA, less cash interest paid, less cash income tax paid, and less capital expenditures.*

(2) *The Company defines Adjusted Free Cash Flow Attributable to WELL Shareholders as Adjusted EBITDA Attributable to WELL Shareholders, less cash interest paid, cash income tax paid and capital expenditures attributable to WELL shareholders. This measure excludes the portion of Adjusted Free Cash Flow attributable to non-controlling interests in the Company's non-wholly owned subsidiaries.*

WELL Health TECHNOLOGIES CORP

Updated Outlook

Disciplined Capital Allocation Program Driving Scale

Updated 2026 Guidance[1]:

Approx. $1.58B Revenue
$185-195M Adj. EBITDA

Canadian Clinics + WELLSTAR

>$1 Billion Revenue[3] run-rate by end of 2028

Sustained >10% Annual Adj. EBITDA Growth[2]

Expanding OneWELL as a Partner to Public Sector

(1) *This guidance includes the effect of $17.6 million in deferred revenue from Circle Medical to be recognized in 2026. For more information regarding this impact, please refer to WELL's Q3-26 MD&A.*
(2) *Inclusive of acquisitions and organic growth, and excludes divestitures.*
(3) *Previously presented as a target for WELL Canada, which included Canadian Clinics, WELLSTAR and other WELL entities, including CYBERWELL and WELL Research. Following WELLSTAR's listing on the TSX Venture Exchange as a separate public company, the target is now presented as Canadian Clinics plus WELLSTAR.*

Contact

Hamed Shahbazi
CEO, Chairman & Founder
hamed@well.company

Evelyn Sutherland
Chief Financial Officer
evelyn.sutherland@well.company

Pardeep Sangha
Investor Relations
investor@well.company

www.well.company

Vancouver, BC
Canada